Non-Member Access fee for Recorded CE Webinar:
The Future of Hepatitis C: A Review of New Medications for the Treatment of Hepatitis C
Non-members are invited to view recorded webinars and receive CE credit for a small fee.
Once your payment has been processed, you will receive an automated email with a link to download an electronic item. Click the link in the email - this will download a PDF file that contains a link to access the recorded webinar.
Please contact PPA's CPE Administrator, Sara Powers, at (717) 234-6151 x. 2 or email@example.com with questions.
Release Date: September 19, 2014
Expiration Date: September 19, 2017
Activity Type: Knowledge-based
CE Credit: 1 Contact Hour (0.1 CEU)
Cost: Free for PPA members! $30 for non-members.
|The Pennsylvania Pharmacists Association is accredited by the Accreditation
Council for Pharmacy Education as a provider of continuing pharmacy education.
In recent years several new oral medications have been evaluated for use in treating Hepatitis C virus infections. Pharmacists may be consulted for assistance with the use of these medications, especially with regards to monitoring and management of adverse events. This session will review these new therapies, their clinical utility, and monitoring and adverse event management recommendations.
At the completion of this activity, the participant will be able to:
1. List the characteristics of new therapies for the treatment of Hepatitis C.
2. Discuss the literature regarding new therapies for the treatment of Hepatitis C.
3. Discuss monitoring for and management of common and major adverse events associated with new therapies for the treatment of Hepatitis C.
Teresa Breslin, PharmD, PGY2 Pharmacy Resident, UPMC St. Margaret
To receive CE credit for this home study, you will need to watch the entire video, complete an online survey evaluation, and pass a short quiz. Access to the survey and quiz will be automatically provided after you have watched the video. PPA must have your CPE Monitor ID and birthday on file to issue credit.